Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Instem PLC said on Tuesday it has secured funding from the European Medicines Agency related to the research of N-nitrosamines, carcinogens humans may consume through tobacco use or eating certain foods.
The European Medicines Agency invested €2.5 million into the research, with Instem receiving 13% of that.
The IT solutions provider, serving life sciences market, is working on a two-year research project to further investigate the mutagenicity of different classes of N-nitrosamines, funded by EMA and led by Fraunhofer Institute for Toxicology & Experimental Medicine.
NAs may be carried by active pharmaceutical ingredients as impurities from production and/or storage or may cause their formation in the gastrointestinal tract.
The project will aim to distinguish highly potent from less potent carcinogens.
Instem shares were up 0.2% at 676.40 pence on Tuesday afternoon in London.
Copyright 2022 Alliance News Limited. All Rights Reserved.